Business
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society ...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n April 11, 2024\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International (\"OARSI\") World Congress 2024. The meeting is being held in\n \n Vienna, Austria\n \n from\n \n April 18-21, 2024\n \n .\n \n \n \"There is a significant unmet medical need for the treatment of osteoarthritis (\"OA\") of the knee especially in patients with moderate disease who are years away from a surgical solution,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia. \"We believe EP-104IAR has the potential to transform the treatment paradigm for this condition by offering a favorable safety profile for chronic therapy, including in diabetic patients who make up one third of OA patients. The Phase\n \n 2b\n \n SPRINGBOARD study met its primary and key secondary endpoints, showing a clinically and statistically meaningful impact on pain, while also demonstrating that EP-104IAR has an encouraging safety profile. In combination with our pre-clinical and MRI results, these data suggest a potential best-in-class candidate in terms of managing cartilage health.\"\n \n \n \n \n Podium Presentation Details\n \n \n \n \n \n Abstract Title\n \n : Efficacy Outcomes in Patients with Knee Osteoarthritis: Per-Protocol Analyses From SPRINGBOARD, a Phase 2, Randomized, 24-Week Study of EP-104IAR (Long-acting Intra-articular Injection of Fluticasone Propionate).\n \n \n \n Session Title\n \n : News in Therapies\n \n \n \n Date\n \n :\n \n April 20, 2024\n \n \n \n \n Presentation Time\n \n : 2:40 &#...